Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009
Cited by 1,351 works. doi:10.1016/s0140-6736(09)60569-9
Authors
- Robert Pirker
- Jose R. Pereira
- Aleksandra Szczęsna
- Joachim von Pawel
- Maciej Jerzy Krzakowski
- Rodryg Ramlau
- Ihor O. Vynnychenko
- Keunchil Park
- Chih-Teng Yu
- Valentyn Ganul
- Jae-Kyung Roh
- Emilio Bajetta
- Kenneth John O'Byrne
- Filippo de Marinis
- Wilfried Eberhardt
- Thomas Goddemeier
- Michael Emig
- Ulrich Gatzemeier
References
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.